Smith & Nephew plc (LON:SN) has been given a consensus recommendation of “Hold” by the eleven ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and three have given a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is GBX 1,796.14 ($22.10).
A number of research analysts have recently issued reports on SN shares. Shore Capital restated a “sell” rating on shares of Smith & Nephew in a research report on Wednesday. Citigroup reduced their price target on shares of Smith & Nephew from GBX 1,700 ($20.92) to GBX 1,670 ($20.55) and set a “neutral” rating on the stock in a research report on Thursday, June 18th. Berenberg Bank increased their price objective on shares of Smith & Nephew from GBX 2,135 ($26.27) to GBX 2,165 ($26.64) and gave the stock a “buy” rating in a report on Thursday, May 7th. UBS Group reaffirmed a “neutral” rating on shares of Smith & Nephew in a report on Tuesday, June 23rd. Finally, Morgan Stanley raised shares of Smith & Nephew to an “overweight” rating and lowered their price objective for the stock from GBX 1,990 ($24.49) to GBX 1,950 ($24.00) in a research note on Thursday, June 4th.
In related news, insider Roland Diggelmann bought 2,125 shares of the company’s stock in a transaction that occurred on Thursday, May 14th. The shares were acquired at an average price of GBX 1,510 ($18.58) per share, with a total value of £32,087.50 ($39,487.45).
About Smith & Nephew
Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.
Read More: What Is An Exchange-Traded Fund (ETF)?
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.